一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Pemetrexed；Carboplatin；H1 Receptor Antagonist；H2 Receptor Antagonist；Acetaminophen (or equivalent)；Dexamethasone (or，当前状态为研究进行中，已停止招募。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Pemetrexed；Carboplatin；H1 Receptor Antagonist；H2 Receptor Antagonist；Acetaminophen (or equivalent)；Dexamethasone (or equivalent)；Steroid Mouthwash (dexamethasone or equivalent) · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 3132) · 合肥
- Beijing Cancer hospital ( Site 3100) · 北京
- Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107) · 北京
- Chongqing University Cancer Hospital-Medical Oncology ( Site 3128) · 重庆
- Fujian Cancer Hospital ( Site 3124) · 福州
- The First Affiliated hospital of Xiamen University ( Site 3125) · 厦门
- Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3102) · 广州
- Guangxi Medical University Affiliated Tumor Hospital-Respiratory Oncology ( Site 3103) · 南宁
- Harbin Medical University Cancer Hospital ( Site 3109) · 哈尔滨
- Henan Cancer Hospital ( Site 3105) · 郑州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 3121) · 武汉
- Hubei Cancer Hospital ( Site 3122) · 武汉
- The Second Xiangya Hospital of Central South University-Oncology ( Site 3104) · 长沙
- Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 3117) · 南京
- The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118) · 苏州
- The Second Affiliated Hospital of Nanchang University ( Site 3119) · 南昌
- The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 3130) · 西安
- Jinan Central Hospital ( Site 3113) · 济南
- Shandong Cancer Hospital ( Site 3112) · 济南
- Zhongshan Hospital of Fudan University ( Site 3133) · 上海
- Shanxi Cancer Hospital ( Site 3114) · 太原
- West China Hospital, Sichuan University ( Site 3126) · 成都
- Sichuan Cancer hospital. ( Site 3127) · 成都
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3101) · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 3106) · 杭州
- The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 3120) · 温州
公开的入选条件
- * Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
- * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
- * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
- * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
- * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
- * Life expectancy of at least 3 months.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06305754；登记信息更新于 2026-09-11。